BioSpace News Archive

Endoscope reprocessing is considered imperative for infection prevention.

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the addition of another site of excellence, the Yale Child Study Center at Yale University, to its Phase IIb clinical trial for SCI-110 in patients suffering from Tourette Syndrome (“TS”).

COUR Pharmaceuticals, today announced the publication of data, in collaboration with the Miller lab at Northwestern University, demonstrating durable tolerance using its novel platform technology in the Non-Obese Diabetic (NOD) model of type 1 diabetes (T1D), the gold standard model for autoimmunity.

It includes conditions such as congenital heart disease, cardiomyopathy, and heart valve disease.

Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its second quarter 2022 financial results after the close of market on Monday, August 8, 2022.

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned joint venture 3CL Pharma Ltd. reported the preprint in ResearchGate of a case study entitled “Tollovid as a Rescue Agent for Paxlovid Rebound in Acute COVID-19”.

OriCell Therapeutics (Shanghai) Co., Ltd. (“OriCell” or “the Company”) has announced the completion of Series B financing totaling over US$120 million.

World Lung Cancer Day serves as a reminder of the importance of lung cancer screenings among high-risk patients, while also offering an opportunity to highlight the advancement made in early detection and treatment that have helped increase the five-year survival rate for non-small cell lung cancer, the most common kind of lung cancer.

Tevogen Bio, a late stage clinical biotechnology company specializing in the development of cell and gene therapies in oncology, neurology, and virology, today announced that it completed enrollment in the Proof-of-Concept clinical trial of the company’s lead investigational product, TVGN-489, for elderly or high-risk ambulatory COVID-19 patients.

Kleiner Device Labs today announced that its new KG™2 Surge™ flow-thru interbody system was used in its first surgical procedure.